Dr Douglas Reznick explains the testing that comes after your initial diagnosis, what that means when selecting a treatment option, and how TAGRISSO® (osimertinib) may be a viable option.
Please see the complete Prescribing Information, including Patient Information for TAGRISSO at www.azpicentral.com/pi.html?p... and on TAGRISSO.com.
SELECT SAFETY INFORMATION
TAGRISSO is an FDA-approved oral targeted therapy used as a first treatment for metastatic non-small cell lung cancer with certain abnormal EGFR gene(s).
TAGRISSO may cause serious side effects. These could lead to death. Tell your healthcare provider right away if you have lung problems, such as trouble breathing, shortness of breath, cough, or fever; heart problems, such as pounding or racing, swelling of your ankles and feet, dizziness, feeling lightheaded, or feeling faint; eye problems, such as watery, red, sensitive, or painful eyes; skin problems, such as skin reactions that look like rings, or severe blistering or peeling of the skin; if you develop signs of inflammation of your blood vessels in your skin, including purple spots or redness of your skin on your lower arms, lower legs, or buttocks or large hives on the main part of your body that do not go away within 24 hours and look bruised; or if you develop signs of blood and bone marrow problems, including new fever or fever that does not go away (≥100.4 °F); easy bruising or bleeding that will not stop; unusually pale skin, infection, tiredness, or weakness. Tell your healthcare provider about all your medical conditions and any medicines you take, and if you are pregnant or plan to become pregnant or are breastfeeding.
The most common side effects of TAGRISSO are low white blood cell counts, low platelet counts, low red blood cell counts (anemia), diarrhea, rash, muscle, bone, or joint pain, changes in your nails, dry skin, mouth sores, and tiredness. These are not all the possible side effects.
31 мар 2024
